AFT Pharmaceuticals (AFT) is continuing to build its business operations in South East Asia by moving to the appointment of a Business Manager based in its Kuala Lumpur office in Malaysia.
“To date we have relied upon consultant services, but now we are delighted to be able to strengthen our operations and we have created positions for specific senior AFT managers in both Malaysia and Singapore,” said Mark Morrison, Director of International Business at AFT.
In addition to the Malaysian position, two additional sales representatives have been appointed to increase the AFT Singapore sales team. The new representatives will report to a Sales Manager following that person’s internal promotion. These new appointees are in preparation for a number of product launches in Singapore next month.
AFT now has 10 products approved for sale in Singapore with a further 12 undergoing regulatory evaluation whilst Malaysia has 4 product approvals and another 13 in process.
AFT Founder and CEO, Dr Hartley Atkinson, says that he is pleased to announce further progress towards the objectives outlined in the company’s Product Disclosure Statement issued last year.
“The expansion of our business in South East Asia continues to be an important growth area for us and these new positions reflect that. The continued push into these markets has been complemented by some significant recent announcements regarding out-licensing of Maxigesic into a range of international markets. As a company, we’re very much focused on growing this business in the way we’ve indicated to the market that we would.”
